SHIPPEO
26.4.2022 12:29:13 CEST | Business Wire | Press release
Shippeo , a leading provider of global shipment visibility, has achieved a significant advancement in its predictive shipment ETA performance, aided by investments in new AI/ML infrastructure and sophisticated algorithms. As a result, shippers and logistics service providers are seeing improved accuracy and reliability of estimated times of arrival (ETAs) of their shipments, thereby increasing the efficiency and predictability of their supply chains.
The recent challenges caused by major supply chain disruptions have reaffirmed the need for organisations to improve shipment traceability on a global scale. Although it has never been easier to track shipments travelling throughout the world in near real-time thanks to more affordable devices and better connectivity, the type of data that supply chain management values is changing.
Shippeo’s Chief Product Officer, Anand Medepalli, says: “The question supply chain managers are asking themselves is shifting from ‘where is my shipment’ at the macro level to a more granular ‘When will it arrive at the next stop?’ and ‘Are there any risks of a delay?’”. This means that the ability to predict shipment ETAs at a very granular level is increasingly becoming a must-have, critical capability for shippers.
This improved ETA brings a range of benefits to manufacturers. Shippeo customers report that having accurate ETA predictions for shipment arrival times improves team productivity at key delivery sites, while boosting KPI performance, increasing sales and, of course, raising customer satisfaction levels. At the same time, these manufacturers, many of which are operating globally, are decreasing stock-outs or production line halts by as much as 76%, as well as reducing late penalties by 25%, dwell times by 30% and reducing unexpected freight costs.
As with any algorithm, ETA accuracy depends heavily on the quality of data inputted, which is why Shippeo’s core R&D focus is to continually enhance the accuracy and reliability of the data feeding the ETA predictions. In its latest third release, in addition to data quality, the company has revamped its machine learning (ML) infrastructure, as well as the methodologies and models its data scientists and ML engineers use. The result is an impressive 32% improvement in ETA accuracy up to 48 hours before a scheduled delivery.
“This is really exciting for us given that several of our customers, including Renault Group, one of the world’s largest automotive manufacturers, have already told us that our ETA is impressive,” says Medepalli.
“Shippeo invests a lot in continually improving its ETA calculator algorithm, taking our feedback as users into account,” says Renan Filleur, Renault Group’s General Manager of Parts Logistic Operations and Performance. “ETA reliability results are an important focus and are made visible, which greatly supports Renault Group’s choice of Shippeo’s real-time visibility platform. This reliability is a critical element for any major industrial customer like Renault due to the genuine value it generates for the business.”
Shippeo is also the only real-time transportation visibility platform vendor offering contractual guarantees on its ETA accuracy, as well as carrier onboarding speed and high tracking rates. “The performance of our ETA model gives us the confidence to guarantee high accuracy for all of our customers or we give their money back,” explains Medepalli, “which means a guaranteed time to value for every customer. This relentless focus on customer satisfaction is what differentiates us from our competition.”
The enhanced ETA algorithm is available now for all Shippeo platform users.
- Ends -
About Shippeo (https://www.shippeo.com
)
LinkedIn
, Facebook
, Twitter
Shippeo, a global leader and European specialist in real-time transportation visibility, helps major shippers and logistics service providers leverage transportation to deliver exceptional customer service and achieve operational excellence. Their Multimodal Visibility Network connects FTL, LTL, parcel, and container transport and integrates 875+ TMS, telematics and ELD systems using a unique API. The Shippeo platform provides instant access to real-time delivery tracking, automates customer processes and offers unmatched ETA accuracy thanks to a proprietary and industry-leading algorithm developed in-house. Hundreds of customers, including global brands like Coca-Cola HBC, Carrefour, Renault Group, Schneider Electric, Total, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 28 million shipments per year across 75 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005484/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release
The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
